MBX Biosciences, Inc. Operating Income Loss

Quick Answer

MBX Biosciences, Inc. reported Operating Income Loss of -$98.06 million for the year ending 2025.

  • MBX Biosciences, Inc. showed a decrease of -43.8% in Operating Income Loss from 2024 to 2025.
  • This data is from MBX Biosciences, Inc.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
  • XBRL data for this metric is available from 2023 to 2025 (3 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 3 years of available data (2023 to 2025), MBX Biosciences, Inc.'s Operating Income Loss has declined by 177.7%.
  • Historical annual values: Fiscal year 2025: -$98.06 million | Fiscal year 2024: -$68.19 million | Fiscal year 2023: -$35.31 million.
  • Data sourced from SEC EDGAR public filings as of June 21, 2026.

Last verified: